A Phase II Trial of Chemotherapy Plus Pembrolizumab in Patients With Advanced NSCLC Previously Treated With PD-1 or PD-L1 Inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029
Latest Information Update: 28 Aug 2023
At a glance
- Drugs Pembrolizumab (Primary) ; Docetaxel; Gemcitabine; Pemetrexed
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 10 Aug 2023 Status changed from active, no longer recruiting to completed.
- 24 Nov 2022 Results assessing the efficacy and safety of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer, published in the Cancer.
- 17 Nov 2021 Planned End Date changed from 1 Feb 2022 to 1 Feb 2023.